


Dr. Robert C. Hastings, Editor IJL



Dr. Robert Hastings, Chief of Pharmacology Research, U.S. Public Health Service Hospital, Carville, Louisiana becomes editor of this JOURNAL with the first issue of Volume 47 for 1979.

He took his premedical training at Vanderbilt University and graduated summa cum laude from the University of Tennessee College of Medicine in 1962 with Alpha Omega Alpha honors.

In 1966 Dr. Hastings became staff physician at Carville and has retained association with this institution, as a commissioned USPHS officer, save for the period 1968-1971 which he spent in graduate studies at Tulane Medical Center. These studies culminated in his receiving the Ph.D. degree in pharmacology. He then resumed work at Carville, becoming chief of the Pharmacology Research Department, the position which he holds at the present. He has retained an ongoing relationship with Tulane University School of Medicine where he is presently clinical associate professor in the Department of Medicine. As of October 1977, he became a member of the U.S. Panel, U.S.-Japan Cooperative Medical Science Program, NIAID.

His research interests reflect this career interest in leprosy centering around the anti-inflammatory effects of thalidomide, chemotherapy of leprosy, and the nature and treatment of leprosy reactions. In addition, he has deep interest and in-depth studies on immunotherapy of leprosy. These were reflected in his recent well-received and scholarly invitational editorial in this JOURNAL, entitled "Transfer Factor as a Probe of the Immune Defect in Lepromatous Leprosy" (IJL 45 [1977] 281-291.)

While not neglecting other journals, Dr. Hastings has well demonstrated an interest in the JOURNAL and in presenting his research findings to the "world of leprosy" by publishing a continuous series of significant papers in this JOURNAL.

It is evident that the new editor is highly competent, has a career interest in leprosy, and will undoubtedly deepen his already committed interest in the IJL. It is anticipated that his work will be greatly facilitated by the remarkably fine facilities at Carville and the strong backing of this well-known leprosy treatment and research institution.

Personally, I wish him well and am confident that he will receive the strong support and interest of the ILA membership.

—OLAF K. SKINSNES